<DOC>
	<DOCNO>NCT01631487</DOCNO>
	<brief_summary>The purpose study investigate safety , tolerability , pharmacokinetics JNJ-39439335 healthy Japanese Caucasian adult male participant Part 1 , healthy Japanese adult male participant Part 2 .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics JNJ-39439335 Healthy Japanese Caucasian Adult Male Participants</brief_title>
	<detailed_description>This double-blind ( neither physician participant know treatment participant receives ) , randomize ( study drug assign chance ) , placebo-controlled study ( placebo inactive substance compare drug test whether drug real effect clinical trial ) . The study consist 2 Parts . In Part 1 , three group healthy Japanese men 3 group healthy Caucasian men receive single oral dose JNJ-39439335 placebo Day 1 . Each group include 8 participant . The study duration Part 1 participant approximately 8 week : screen phase 28 day prior dose , treatment phase 14 day , follow-up phase 14 to16 day . In Part 2 , three group healthy Japanese men receive once-daily dos either JNJ-39439335 placebo 21 day . Each group include 12 participant . The study duration Part 2 participant approximately 11 week : screen phase 28 day prior dose , treatment phase 21 day , follow-up phase approximately 28 day . During treatment phase , participant remain study unit . Blood sample urine collect drug concentration measurement laboratory safety assessment .</detailed_description>
	<criteria>Japanese Caucasian participant Nonsmoker Body Mass Index ( BMI ) 18 30 kg/m2 , inclusive , body weight less 50 kg Healthy basis physical examination , vital sign , hematology , coagulation , serum chemistry ( include liver function test ) urinalysis Willing adhere prohibition restriction specify study protocol Oral temperatures &gt; 37.5 Celsius degree Participants occupation hobby routinely expose situation could sustain thermal burn Abnormal electrocardiogram ( ECG ) result Clinically significant abnormal value hematology , clinical chemistry urinalysis History current clinically significant medical illness investigator considers exclude participant could interfere interpretation study result</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-39439335</keyword>
	<keyword>Japanese</keyword>
	<keyword>Caucasian</keyword>
	<keyword>Male</keyword>
</DOC>